


## IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) A compound of the formula I,



I

or a pharmaceutically acceptable salt or ester thereof,

in which

R1, R2, R3, R4, R5, R6 independently of one another are (C<sub>0</sub>-C<sub>30</sub>)-

alkylene-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=O)-, -CH=CH-, -C≡C-, -N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)-, -N((C<sub>1</sub>-C<sub>6</sub>)-alkylphenyl)- or -NH-; or

H, F, Cl, Br, I, CF<sub>3</sub>, NO<sub>2</sub>, CN, COOH, COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl or O-(C<sub>1</sub>-C<sub>6</sub>)-

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; or

SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(CH<sub>2</sub>)<sub>n</sub>-phenyl, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO-(CH<sub>2</sub>)<sub>n</sub>-phenyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-phenyl,

where n = 0 – 6 and the phenyl radical may be substituted up to two times by F, Cl, Br, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl or NH<sub>2</sub>; or

NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, NH(C<sub>1</sub>-C<sub>7</sub>)-acyl, phenyl, O-(CH<sub>2</sub>)<sub>n</sub>-phenyl, where n = 0 – 6, where the phenyl ring may be mono- to trisubstituted by F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or CONH<sub>2</sub>;

(LAG) is a sugar residue, disugar residue, trisugar residue, tetrasugar residue; a sugar acid, an amino sugar; an amino acid residue, an oligopeptide residue comprising 2 to 9 amino acids; a trialkylammoniumalkyl radical; or -O-(SO<sub>2</sub>)-OH;

wherein at least one of the radicals R1 to R6 has the meaning (C<sub>0</sub>-C<sub>30</sub>)-alkylene-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=O)-, -CH=CH-, -C≡C-, -N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)-, -N((C<sub>1</sub>-C<sub>6</sub>)-alkylphenyl)- or -NH-, and where the radicals R1 and R2 may not have the meaning -O-sugar residue or -O-sugar acid.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER <sup>LLP</sup>

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

2. (Original) A compound as claimed in claim 1, wherein

R1, R2, R3, R4, R5, R6 independently of one another are (C<sub>0</sub>-C<sub>30</sub>)-

alkylene-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=O)-, -N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)- or -NH-; or

H, F, Cl, Br, I, CF<sub>3</sub>, NO<sub>2</sub>, CN, COOH, COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl or O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; or

SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(CH<sub>2</sub>)<sub>n</sub>-phenyl, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO-(CH<sub>2</sub>)<sub>n</sub>-phenyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-phenyl, where n = 0 - 6 and the phenyl radical may be substituted up to two times by F, Cl, Br, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl or NH<sub>2</sub>; or

NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, NH(C<sub>1</sub>-C<sub>7</sub>)-acyl, phenyl or O-(CH<sub>2</sub>)<sub>n</sub>-phenyl, where n = 0 - 6 and the phenyl ring may be mono- to trisubstituted by F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or CONH<sub>2</sub>;

(LAG) is a sugar residue, disugar residue, trisugar residue, tetrasugar residue;

a sugar acid, an amino sugar;

an amino acid residue, an oligopeptide residue comprising 2 to 9 amino acids;

a trialkylammoniumalkyl radical; or -O-(SO<sub>2</sub>)-OH;

wherein at least one of the radicals R1 to R6 has the meaning (C<sub>0</sub>-C<sub>30</sub>)-alkylene-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=O)-, -N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)- or -NH-, and where the radicals R1 and R2 may not have the meaning -O-sugar residue or -O-sugar acid.

3. (Original) A compound as claimed in claim 1, wherein

R1, R2, R3, R4, R5, R6 independently of one another are (C<sub>0</sub>-C<sub>30</sub>)-alkylene-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -O-, -(C=O)-, -N(C<sub>3</sub>)- or -NH-; or

H, F, Cl, Br, I, CF<sub>3</sub>, NO<sub>2</sub>, CN, COOH, COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl or O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; or

SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(CH<sub>2</sub>)<sub>n</sub>-phenyl, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO-(CH<sub>2</sub>)<sub>n</sub>-phenyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-phenyl, where n = 0 – 6 and the phenyl radical may be substituted up to two times by F, Cl, Br, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl or NH<sub>2</sub>; or

NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, NH(C<sub>1</sub>-C<sub>7</sub>)-acyl, phenyl or O-(CH<sub>2</sub>)<sub>n</sub>-phenyl, where n = 0 – 6 and the phenyl ring may be mono- to trisubstituted by F, Cl, Br, I, -

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or CONH<sub>2</sub>;

(LAG) is a sugar residue, disugar residue, trisugar residue, tetrasugar residue;  
a sugar acid; an amino sugar;  
an amino acid residue, an oligopeptide residue comprising 2 to 9 amino acids;  
a trialkylammoniumalkyl radical; or -O<sub>2</sub>-(SO<sub>2</sub>)-OH;

wherein at least one of the radicals R1 or R6 has the meaning (C<sub>0</sub>-C<sub>30</sub>)-alkylene-(LAG), where one or more carbon atoms of the alkylene radical may be replaced by -O-, - (C=O)-, -N(CH<sub>3</sub>)- or -NH-, and where the radicals R1 and R2 may not have the meaning -O-sugar residue or -O-sugar acid.

4. (Original) A compound as claimed in claim 1, wherein

R1, R2, R3, R4, R5, R6 independently of one another are

-(CH<sub>2</sub>)<sub>0-1</sub>-NH-(C=O)<sub>0-1</sub>-(C<sub>3</sub>-C<sub>25</sub>)-alkylene-(C=O)<sub>0-1</sub>-N(R7)<sub>0-1</sub>-LAG, where one or more carbon atoms of the alkylene radical may be replaced by oxygen atoms, or

H, F, Cl, Br, I, CF<sub>3</sub>, NO<sub>2</sub>, CN, COOH, COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl or O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, where one, more or all hydrogens in the alkyl radicals may be replaced by fluorine; or

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

SO<sub>2</sub>-NH<sub>2</sub>, SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, S-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S-(CH<sub>2</sub>)<sub>n</sub>-phenyl, SO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO-(CH<sub>2</sub>)<sub>n</sub>-phenyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-phenyl, where n = 0 – 6 and the phenyl radical may be substituted up to two times by F, Cl, Br, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl or NH<sub>2</sub>; or NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, NH(C<sub>1</sub>-C<sub>7</sub>)acyl, phenyl or O-(CH<sub>2</sub>)<sub>n</sub>-phenyl, where n = 0 - 6 and the phenyl ring may be mono- to trisubstituted by F, Cl, Br, I, OH, CF<sub>3</sub>, NO<sub>2</sub>, CN, OCF<sub>3</sub>, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>, SO<sub>2</sub>-CH<sub>3</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or CONH<sub>2</sub>;

R7 is H or CH<sub>3</sub>;

(LAG) is a sugar residue;

where one of the radicals R1 or R3 has the meaning -(CH<sub>2</sub>)<sub>0-1</sub>-NH-(C=O)<sub>0-1</sub>-(C<sub>3</sub>-C<sub>25</sub>)-alkylene-(C=O)<sub>0-1</sub>-N(R7)<sub>0-1</sub>-LAG, where one or more carbon atoms of the alkylene radical may be replaced by oxygen atoms.

5. (Original) A pharmaceutical composition comprising one or more of the compounds as claimed in claim 1 and a pharmaceutically acceptable carrier.

6. (Currently Amended) A pharmaceutical composition combination comprising one or more compounds as claimed in claim 1 and at least one further pharmacologically active compound.

7. (Currently Amended) A pharmaceutical ~~composition~~ combination as claimed in claim 6, comprising, as a further active compound, one or more compounds that ~~normalize~~ affect lipid metabolism.

8. (Currently Amended) A pharmaceutical ~~composition~~ combination as claimed in claim 6, comprising, as a further active compound, one or more compounds chosen from:

antidiabetics, hypoglycemically active compounds, HMGCoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbers, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP citrate lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonyl ureas, biguanides, meglitinides, thiazolidindiones,  $\alpha$ -glucosidase inhibitors, active compounds which act on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists,  $\beta$ 3 agonists, MSH (melanocyt-stimulating hormone) agonists, CCK agonists, serotonin-reuptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, decoupling protein 2- or 3-modulators, leptin agonists, DA agonists,

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR- $\beta$ -agonists or amphetamines.

9. (Withdrawn) A method for the treatment of impaired lipid metabolism, which comprises administering to a host in need of the treatment an effective amount of at least one compound as claimed in claim 1.

10. (Canceled)

11. (Withdrawn) A method for the treatment of hyperlipidemia, which comprises administering to a host in need of the treatment an effective amount of at least one compound as claimed in claim 1.

12. (Canceled)

13. (Withdrawn) A method for controlling the serum cholesterol concentration in a host, which comprises administering to the host in need of the control of serum cholesterol concentration an effective amount of at least one compound as claimed in claim 1.

14. (Withdrawn) A method for treating insulin resistance, which comprises administering to a host in need of the treatment an effective amount of at least one compound as claimed in claim 1.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



15. (Canceled)

16. (Withdrawn) A method for the treatment of an arteriosclerotic manifestation, which comprises administering to a host in need of the treatment an effective amount of at least one compound as claimed in claim 1.

17. (Canceled)

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER <sup>LLP</sup>

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)